Takeda to Spend $300 Million to Expand Biotech Manufacturing Site

Takeda said it plans to spend nearly $300 million to expand its biotechnology manufacturing site and build a carbon net-zero emissions warehouse in Lessines, Belgium. The plan also includes dedicated employee training in concert with Belgium’s ecosystem of universities, biotech federations and training centers.

The company said the update will involve a new production facility for the manufacturing of plasma-derived therapies for patients with rare and complex chronic diseases.

Examples of these diseases include primary or acquired immunodeficiencies, hereditary angioedema and bleeding disorders.

The investment is the largest to date for Takeda in Belgium.

The Lessines site is 50 years old.